Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision.
Fiche du document
- doi: 10.1002/jimd.12370
- issn: 0141-8955
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/doi/10.1002/jimd.12370
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/pmid/33595124
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/eissn/1573-2665
Ce document est lié à :
info:eu-repo/semantics/altIdentifier/urn/urn:nbn:ch:serval-BIB_859249D2C7284
info:eu-repo/semantics/openAccess , CC BY-NC-ND 4.0 , https://creativecommons.org/licenses/by-nc-nd/4.0/
Sujets proches
ProofCiter ce document
P. Forny et al., « Guidelines for the diagnosis and management of methylmalonic acidaemia and propionic acidaemia: First revision. », Serveur académique Lausannois, ID : 10.1002/jimd.12370
Métriques
Partage / Export
Résumé
Isolated methylmalonic acidaemia (MMA) and propionic acidaemia (PA) are rare inherited metabolic diseases. Six years ago, a detailed evaluation of the available evidence on diagnosis and management of these disorders has been published for the first time. The article received considerable attention, illustrating the importance of an expert panel to evaluate and compile recommendations to guide rare disease patient care. Since that time, a growing body of evidence on transplant outcomes in MMA and PA patients and use of precursor free amino acid mixtures allows for updates of the guidelines. In this article, we aim to incorporate this newly published knowledge and provide a revised version of the guidelines. The analysis was performed by a panel of multidisciplinary health care experts, who followed an updated guideline development methodology (GRADE). Hence, the full body of evidence up until autumn 2019 was re-evaluated, analysed and graded. As a result, 21 updated recommendations were compiled in a more concise paper with a focus on the existing evidence to enable well-informed decisions in the context of MMA and PA patient care.